Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Eli Lilly and Company

Clinicaltrial registered28 Oct 2026

Eli Lilly and Company

28 Oct 2026: Trial registered · A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
28 Oct 2026
Title
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Conditions
Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
Phase
Phase 3
Study Type
Interventional
Status
Not Yet Recruiting
Countries
United States, Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, Spain, Turkey (Türkiye), Ukraine
Country
United States
Reference
NCT07900633
Location
United States, Argentina, Australia
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Eli Lilly and Company

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Eli Lilly and Company in our registers.

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.